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http://dx.doi.org/10.1016/j.pedneo.2
1875-9572/Copyright ª 2014, TaiwanBackground: The ubiquitin proteasome system plays an exceptional biological role in the
antigen processing and immune response and it could potentially be involved in pathogenesis
of many immunity-related diseases, including juvenile idiopathic arthritis (JIA).
Methods: The PSMB5 (rs11543947), PSMA6 (rs2277460, rs1048990), PSMC6 (rs2295826,
rs2295827), and PSMA3 (rs2348071) proteasomal genes were genotyped on JIA subtype- and
sex-specific association; plasma proteasome levels was measured in patients having risk and
protective four-locus genotypes and eventual functional significance of allele substitutions
was evaluated in silico.
Results: Loci rs11543947 and rs1048990 were identified as disease neutral and other loci as
disease susceptible (p < 0.05). The rs2277460, rs2295826, and rs2295827 loci had the strongest
association with oligoarthritis [odds ratio (OR) Z 2.024, 95% confidence interval (CI) 1.101
e3.722; OR Z 2.371, 95% CI 1.390e4.044; OR Z 2.183, 95% CI 1.272e2.737, respectively),
but the rs2348071 locus was associated with polyarthritis in females (OR Z 3.438, 95% CI
1.626e7.265). A strong (p < 0.001) association was detected between the rs2277460/
rs2295826/rs2295827/rs2348071 four-locus genotypes and the healthy phenotype when all loci
were homozygous on common alleles (OR 0.439, 95% CI 0.283e0.681) and with the disease
phenotype when the rs2348071 and the rs2295826 and/or rs2295827 loci were represented
by risk genotypes simultaneously (OR 4.674, 95% CI 2.096e10.425). Rarely observed in controls,
the double rs2277460/rs2348071 heterozygotes were rather frequent in affected males andd Bioinformatics, Institute of Biology of the University of Latvia, Miera Str. 3, LV2169 Salaspils, Latvia.
du.lv (T. Sjakste).
014.01.007
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394 T. Sjakste et almore strongly associated with polyarthritis (p < 0.05). Haplotypes carrying the rare rs2295826/
rs2295827 and rs2277460 alleles showed a strong (p < 0.001) association with oligo- and poly-
arthritis, respectively. The plasma proteasome level was found to be significantly higher in fe-
males having four-locus risk genotypes compared with protective genotypes (p < 0.001).
Sequence affinity to transcription factors and similarity to splicing signals, microRNAs and/
or hairpin precursors potentially depend on allele substitutions in disease susceptible loci.
Conclusion: We demonstrate for the first time evidence of a sex-specific association of PSMA6/
PSMC6/PSMA3 genetic variants with subtypes of JIA and plasma proteasome concentrations.
Theoretical models of the functional significance of allele substitutions are discussed.
Copyright ª 2014, Taiwan Pediatric Association. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
Juvenile idiopathic arthritis (JIA) is the most common
clinically heterogeneous chronic rheumatic disease in chil-
dren.1 Onset-specific clinical features allow discrimination
of seven JIA subtypes,2 with oligoarthritis (JIoA) and poly-
arthritis (JIpA) being the most frequent.1 The cause of JIA is
complex, involving both environmental and genetic risk
factors. The latter could include structural variations in
both human leukocyte antigens and non-human leukocyte
antigen candidate genes.3,4,5 Because of the pleiotropic
effect, a frequent phenomenon in complex human traits
and diseases,5 some loci of susceptibility may be shared
with other autoimmune diseases.4,5
An exceptional biological role for the ubiquitin protea-
some system (UPS) in antigen processing and immune
response, as suggested by Kloetzel,6 has been increasingly
supported this last decade experimentally. A special form
of proteasomes, thymoproteasomes, expressed exclusively
in the cortex of the thymus and probably involved in posi-
tive selection of T cells, has recently been described. This
indicates that the role of proteasomes in the immune
response might be even more important.7,8 In patients with
systemic autoimmune disease, the concentration of circu-
lating proteasomes has been shown to be strongly
increased8,9; the core 20S proteasome was identified as a
target of the humeral autoreactive immune response.10e15
The proteasomal inhibitor MG132 has been reported to
reduce the severity of arthritis and reverse pain behavior in
arthritic rat models.16
Highly conserved from an evolutionary standpoint, pro-
teasomal genes appear to be subject to multiple trait
purifying selection. Structural variations in proteasomal
genes could potentially affect UPS efficiency through
modulation of expression of a particular gene, realization
of gene and protein networks and metabolic processes that
may in the end influence predisposition to and/or devel-
opment of autoimmune disorders.
The distribution of proteasomal genes over the human
genome displays a tendency of clustering in chromosomes.
Nine of the proteasomal genes have been localized in the
long arm of chromosome 14, including two b (PSMB5 and
PSMB11) and two a (PSMA3 and PSMA6) subunits of the core
20S proteasome, ATPases (PSMC1 and PSMC6), 11S non-
ATPase activators (PSME1 and PSME2) and the PSMA3Ppseudogene. The 14q11, 14q13, and 14q22-32 regions car-
rying the mentioned genes have been reported previously
as potentially susceptible to autoimmune,17e24 and other
complex diseases in European and/or Asian pop-
ulations.Suppl 1e15 Fine 14q13.2 microsatellite scanning
revealed evidence of JIA association with variability in the
region encompassing the PSMA6 gene.24
The aim of the current study was to genotype six single
nucleotide polymorphisms (SNPs) belonging to the PSMA6
(rs2277460 and rs1048990), PSMA3 (rs2348071), PSMB5
(rs11543947) and PSMC6 (rs2295826 and rs2295827) pro-
teasomal genes for subtype- and sex-specific association
with JIA; to evaluate plasma proteasome levels in JIA pa-
tients of different multi locus genotypes, and to perform an
in silico prediction of eventual functional consequences of
nucleotide substitutions, including sequence affinity to
transcription factors (TFs) and similarity to splicing signals
and microRNAs.
2. Materials and methods
2.1. Caseecontrol study
Patients were 174 JIA children (108 girls) receiving consul-
tation at the outpatient clinic of P. Stradins Clinical Uni-
versity Hospital and Children Clinical University Hospital
Clinic Gailezers in Riga, Latvia. JIA was diagnosed and
assignment of the JIA patients to subgroups was carried out
according to the criteria of the International League of
Association for Rheumatology.2 For association analysis
both persistent and extended JIoA, and rheumatoid factor-
negative and rheumatoid factor-positive JIpA subgroups
were combined in JIoA and JIpA groups of 107 and 55 pa-
tients, respectively. Twelve other patients were diagnosed
as having systemic (nZ 9), enthesitis-related (nZ 2), and
psoriatic (n Z 1) arthritis.
The control group was represented by 191 (117 women)
patents of Riga Bikernieki Hospital admitted with a diag-
nosis of trauma and not diagnosed as having any autoim-
mune and/or cardiovascular disorders, type 2 diabetes
mellitus (T2DM), or obesity.
Informed consent was obtained from all the study par-
ticipants or their parents. The study was approved by the
Central Medical Ethics Committee of the Republic of Latvia
Ministry of Health.
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Due to limited data on the genetic diversity and suscepti-
bility to diseases of proteasomal genes, several criteria were
taken into account in choosing markers. These included the
existence of previously reported findings on locus associa-
tion with human health status, locus allele-specific potential
to be functionally significant, locus variability in Latvians,
HardyeWeinberg expectations and others concerning mainly
a genotyping technology. The rs2277460 and rs1048990 of
the PSMA6, rs2295826 and rs2295827 of the PSMC6 and
rs23480071 of the PSMA3 were previously studied on disease
susceptibilitySuppl 1e12,14e16 and/or genetic diversitySuppl 17;
rs11543947 of the PSMB5 gene was previously genotyped on
genetic diversity only in HapMap populations. All loci fit all
other mentioned criteria of marker choice.
2.3. DNA extraction and genotyping
DNA was extracted using a kit for genomic DNA extraction
from nucleated blood cells (Fermentas, Vilnius, Lithuania).
Genotyping methods and primer sequences are indicated in
Supplementary Table 1. Basic PCR was performed with
DreamTaq polymerase (Fermentas) using the following pa-
rameters: 94C for 5 minutes; then 35e40 cycles of 94C for
45 seconds, appropriate annealing temperature (55e61C)
for 45 seconds, 72C for 45 seconds and a final extension
step at 72C for 7 minutes. DNA digestion by restriction
enzymes was performed according to the manufacturer’s
protocols (Fermentas).
Amplified and digested products were analyzed by
electrophoresis in 1e3% agarose gel for all markers. For
quality control, 16 randomly chosen samples for each
marker were genotyped in duplicate in different experi-
ments. The concordance of the genotyping was 100%.
Genotyping data were verified by direct sequencing of the
corresponding DNA fragments in both directions using the
Applied Biosystems 3130xl Genetic Analyzer. Alleles and
genotype frequencies for the rs11543947 (ss69150930),
rs2277460 (ss24557113), rs1048990 (ss35076445), rs2295826
(ss3239727 and ss69157456), rs2295827 (ss23619651) and
rs2348071 (ss3302481) were obtained for HapMap-CEU
(NorthWestern European), YRI (Yoruba), JPT (Japanese),
and HCB (Han Chinese) populations from publicly available
dbSNP (build 13) entries at NCBI (http://www.ncbi.nlm.nih.
gov/snp/). Loci description and nucleotide numbering are
given according to the recommended nomenclature system
(http://www.genomic.unimelb.edu.au/mdi/mutnomen/
recs.html). Sequence information for the chromosome 14
GRCh37.p5 assembly (NCBI reference sequence:
NC_000014.8) was used for loci description, nucleotide
numbering, and primer design using the Primer 3.0
program.
2.4. Measurement of plasma proteasome
concentration
Plasma samples were available only for 23 JIA patients.
These plasma samples were obtained from patients
randomly chosen for plasma sampling during development of
the DNA collection in the JIA study. Therefore, preliminaryinformation on genotypes of these patients did not exist at
the moment of the sampling. Blood was harvested on citrate
anticoagulant, and plasma stored at e80C. Plasma protea-
some concentration was measured in triplicate for each
sample using a standard 20S/26S Proteasome ELISA kit (BML-
PW0575; ENZO Life Sciences, Farmingdale, NY, USA) accord-
ing to the manufacturer’s protocols. Absorbance was read at
450 nm using a UV-Vis spectrometric plate reader. Results
were expressed as concentration of proteasome protein in
ng/mL determined by interpolation for the absorbance value
using the generated 20S proteasome standard curve.2.5. Data analysis
Documenting personalized genotyping data allowed deter-
mination of rs11543947/rs2277460/rs1048990/rs2295826/
rs2295827/rs2348071 six-locus genotype (6-LG) of each in-
dividual participant of the study. The 6-LGs, rs2277460/
rs2295826/rs2295827/rs2348071 four-locus genotypes (4-
LGs), observed haplotypes, single locus genotypes (SLGs),
and allele frequencies were estimated by direct counting of
genetic variants. Inferred haplotypes prediction, haplotype
sorting, estimation of the linkage disequilibrium and prob-
ability of recombination were performed using the DnaSP
software version 5.10.1 online tool at http://www.ub.es/
dnasp.Suppl 18 Both the two-tailed Fisher’s exact test and
the c2 test were applied to evaluate the linkage between
the rs2295826 and rs2295827 polymorphic sites at three
p-value levels (p < 0.05; p < 0.01; p < 0.001). The Bon-
ferroni correction included in the DnaSP analysis was taken
into account to support the significance of the revealed
disequilibrium (a0 Z 0.05).
Deviation from the HardyeWeinberg equilibrium and
differences between cases and controls in allele, genotype
and haplotype frequencies were evaluated by c2 and
CochraneArmitage trend test using XLSTAT 2013 software
for Windows. Genetic models for every individual locus were
designed according to Lewis.Suppl 19 Contingency tables were
2  3 for the AA, AB, BB genotypes in the general model;
2  2 for the AA, ABþBB and AAþAB, BB, and AB, AAþBB
genotypes in the dominant, recessive, and over dominant
models, respectively and A and B alleles in the multiplica-
tive model where A is the major allele and B is the minor
allele. Using an additivemodel, the AA, AB, and BB genotype
distribution was analysed using the CochraneArmitage test
for trend. An odds ratio (OR)> 2 and<0.5 was considered to
be clinically significant. Stratification was performed by JIoA
and JIpA ILAR subtypes and by sex.
Levels of plasma proteasome were expressed as
mean  standard error of the mean for each sample to show
the variability associated with the estimation, and as
mean  standard deviation to characterize the spread of a
data set within the groups. Both standard error of the mean
and standard deviation were calculated using the online
NCalculators (http://ncalculators.com/). Differences in
plasma proteasome levels between the groups were esti-
mated by nonparametric ManneWhitney and/or Krus-
kaleWallis tests using XLSTAT 2013 software. Results were
considered to be of nominal statistical significance at
p < 0.05, moderate statistical significance at p < 0.002,
and strong statistical significance at p < 0.001.Suppl 20
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An eventual functional significance of the SNPs showing
evidence of association was analyzed in silico on sequence
similarity to transcription factors binding sites (TFBSs) using
Genomatix software, MatInspector, Release 7.4 online tool,
at www.genomatix.de.Suppl 21 Only parameters with core/
matrix similarity of > 1.000/0.800 were taken into account.
Splicing signals were predicted by Human Splicing Finder
Version 2.4 (http://www.umd.be/HSF)Suppl 22 with standard
threshold values for branch point, donor and acceptor
splice sites, enhancer, silencer, heterogeneous nuclear
ribonucleoprotein (hnRNP) and other splicing motifs.
Sequence similarity to mature microRNAs and hairpin pre-
cursors was evaluated, and microRNA targets prediction
was done using miRBase (http://www.mirbase.org/index.
shtml)Suppl 23 and miRNAMap (http://mirnamap.mbc.nctu.
edu.tw/index.php)Suppl 24 online tools, respectively.
3. Results
3.1. Genotyping results and single locus association
In both case and control cohorts, the genotyping call rate
was 100% and all six markers were found to be in Har-
dyeWeinberg equilibrium. Allele and genotype spectrumTable 1 Data on the significant associations between single loc
Groups of comparison Marker ID Genetic model Risk factor
(allele or
genotype)
Group 1 Group 2
JIA (174) C (191) rs2277460 Multiplicative a: A
Dominant g: CA
rs2295826 Multiplicative a: G
Dominant g: AG þ GG
rs2295827 Multiplicative a: T
Dominant g. CT þ TT
rs2348071 Overdominant g: AG
JIA-F (108) C-F (117) rs2295826 Multiplicative a: G
Dominant g: AG þ GG
rs2295827 Multiplicative a: T
Dominant g. CT þ TT
rs2348071 Overdominant g: AG
JIoA (107) C (191) rs2277460 Multiplicative a: A
Dominant g: CA
rs2295826 Multiplicative a: G
Dominant g: AG þ GG
rs2295827 Multiplicative a: T
Dominant g. CT þ TT
rs2348071 Overdominant g: AG
JIoA-F (63) C-F (117) rs2295826 Multiplicative a: G
Dominant g: AG þ GG
rs2295827 Multiplicative a: T
Dominant g. CT þ TT
JIpA (55) C (191) rs2348071 Overdominant g: AG
JIpA-F (39) C-F (117) rs2348071 Overdominant g: AG
p < 0.002 and odds ratio > 2 are indicated in bold.
JIA Z juvenile idiopathic arthritis; JIoA Z juvenile idiopathic oligo
F Z female; a Z risk allele; g Z risk genotype.and distributions in Latvians were found to be similar to
those of other Europeans (CEU) for all SNPs studied and to
the Yoruba population (YRI) for the rs2348071; however,
Latvians differ from YRI for resting loci and for all loci from
Japanese (JPT) and Han Chinese (HCB) populations
(Supplementary Table 2).
The rs11543947 and rs1048990 markers showed similar
levels of variation in controls and JIA patients without sig-
nificant differences between the JIoA and JIpA subtypes
and females and males. These markers were considered to
be JIA neutral, while other markers were found to be JIA
susceptible (Table 1).
The rs2277460 showed nominal association (P < 0.05)
with JIA, with highest risk effect for JIoA [ORZ 2.024, 95%
confidence interval (CI) 1.101e3.722]. Alleles and geno-
types frequencies of the rs2295826 and rs2295827 were the
same between each other in the controls and slightly
different in JIoA females with an r2Z 0.936 and D0 of 1.000
[this result is similar to data obtained for Tuscans in Italy
(HapMap TSI): r2Z 0.923], suggesting the existence of rare
GC haplotype in JIA patients. Both markers were found to
be in moderate (p < 0.002) association with JIoA
(OR Z 2.371, 95% CI 1.390e4.044; and OR Z 2.183, 95% CI
1.272e2.737 for the rs2295826 and rs2295827 risk geno-
types, respectively). Moderate association was also detec-
ted for the rs2348071 heterozygous genotype (p < 0.002)
with risk effect for JIpA in the combined cohortus variations and JIA.
Risk factor number (%) p OR CI
Group 1 Group 2
40 (11.49) 25 (6.54) <0.05 1.855 1.104e3.114
40 (22.99) 25 (13.09) <0.05 1.982 1.149e3.419
64 (18.39) 40 (10.47) <0.05 1.927 1.262e2.942
55 (31.61) 36 (18.85) <0.05 1.990 1.230e3.210
61 (17.53) 40 (10.47) <0.05 1.817 1.186e2.784
53 (30.46) 36 (18.85) <0.05 1.886 1.163e3.057
87 (50.00) 66 (34.55) <0.05 1.894 1.245e2.882
46 (21.30) 30 (12.82) <0.05 1.840 1.116e3.033
40 (37.04) 27 (23.07) <0.05 1.932 1.086e3.432
43 (19.91) 30 (12.82) <0.05 1.690 1.020e2.801
38 (35.18) 27 (23.07) <0.05 1.810 1.013e3.232
57 (52.78) 40 (34.19) <0.05 2.151 1.261e3.672
25 (11.68) 25 (6.54) <0.05 1.889 1.061e3.362
25 (23.36) 25 (13.09) <0.05 2.024 1.101e3.722
45 (21.03) 40 (10.47) <0.001 2.277 1.435e3.612
38 (35.51) 36 (18.84) <0.002 2.371 1.390e4.044
42 (19.63) 40 (10.47) <0.002 2.088 1.308e3.333
36 (33.64) 36 (18.84) <0.002 2.183 1.272e2.737
50 (46.73) 66 (34.56) <0.05 1.661 1.027e2.687
31 (24.60) 30 (12.82) <0.05 2.219 1.275e3.861
26 (41.27) 27 (23.07) <0.05 2.342 1.216e4.511
28 (22.22) 30 (12.82) <0.05 1.943 1.105e3.416
24 (38.09) 27 (23.07) <0.05 1.943 1.105e3.416
32 (58.18) 66 (34.56) <0.002 2.635 1.434e4.841
25 (64.10) 40 (34.19) <0.002 3.438 1.626e7.265
arthritis; JIpA Z juvenile idiopathic polyarthritis; C Z control;
Table 2 Four-loci genotypes (4-LGs) presentation and results of significant associations with juvenile idiopathic arthritis (JIA).
4-LG configurations 4-LGs number (%) in the groups and association results
No. Genotype of individual locus Controls JIA JIoA JIpA
PSMA6 PSMC6 PSMA3 All
n Z 191
F
n Z 117
M
n Z 74
All
n Z 174
F
n Z 108
M
n Z 66
All
n Z 107
F
n Z 63
M
n Z 44
All
n Z 55
F
n Z 39
M
n Z 16L1 L2 L3 L4
1P;Ref CC AA CC GG or
AA
86
(45.03)
52
(44.44)
34
(45.95)
46
(26.44)
24
(22.22)
22
(33.33)
32
(29.91)
17
(26.98)
15
(34.09)
11
(20.00)
6
(15.38)
5
(31.25)
Association in
the groups:
p OR 95% CI
JIA vs. C <0.001 0.439 0.283e0.681
JIA-F vs. C-F <0.001 0.357 0.200e0.637
JIoA vs. C <0.05 0.521 0.316e0.859
JIoA-F vs. C-F <0.05 0.462 0.239e0.859
JIpA vs. C <0.001 0.305 0.150e0.620
JIpA-F vs. C-F <0.002 0.227 0.091e0.568
2N CC AA CC GA 48
(25.13)
28
(23.93)
20
(27.03)
44
(25.29)
30
(27.78)
14
(21.21)
20
(18.69)
12
(19.05)
8
(18.18)
19
(34.55)
15
(38.46)
4
(25.00)
3N CC AG
GG
CT
TT
GG or
AA
22
(11.52)
18
(15.39)
4
(5.41)
19
(10.92)
14
(12.96)
5
(7.58)
11
(10.28)
7
(11.11)
4
(9.09)
7
(12.73)
6
(15.38)
1
(6.25)
4N CA AA CC GG or AA 16
(8.38)
7
(5.98)
9
(12.16)
16
(9.20)
9
(8.33)
7
(10.61)
9
(8.41)
6
(9.52)
3
(6.82)
4
(7.27)
2
(5.13)
2
(12.50)
5R CC AG
GG
GG
CT
TT
CC
GA 10
(5.24)
7
(5.98)
3
(4.05)
25
(14.37)
19
(17.59)
6
(9.09)
19
(17.76)
14
(22.22)
5
(11.36)
6
(10.91)
5
(12.82)
1
(6.25)
Association in
the groups:
p OR CI
JIA vs. C <0.001 4.674 2.096e10.425
JIA-F vs. C-F <0.001 5.881 2.231e15.500
JIoA vs. C <0.001 5.106 2.179e11.968
JIoA-F vs. C-F <0.001 6.118 2.175e17.210
JIpA vs. C <0.05 4.691 1.477e14.897
JIpA-F vs. C-F <0.05 6.190 1.574e24.343
6R CA AA CC AG 5
(2.62)
3
(2.57)
2
(2.70)
13
(7.47)
5
(4.63)
8
(12.12)
8
(7.48)
2
(3.17)
6
(13.64)
5
(9.09)
3
(7.69)
2
(12.50)
Association in
the groups:
p OR CI
JIA vs. C <0.05 4.861 1.625e13.940
JIA-M vs. C-M <0.05 6.182 1.370e27.895
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398 T. Sjakste et al(OR Z 2.635, 95% CI 1.434e4.841) and JIpA females
(OR Z 3.438, 95% CI 1.626e7.265).
In both the control and case groups, risk genotypes were
more frequent in males for the rs2277460 locus and in fe-
males for the rs2295826 and rs2295827 loci; the rs2348071
heterozygous risk genotype was more frequent in females
than in males in JIpA patients (Supplementary Table 2).
3.2. Identification of the risk/protective 4-LGs
Personalized genotyping data documentation allowed
analysis of the spectrum and frequencies in the groups of
the 4-LGs rs2277460/rs2295826/rs2295827/rs2348071
(Table 2) composed from loci individually susceptible to
disease (Table 1). Nineteen 4-LGs observed in both case and
control groups were classified by eight categories according
to presence/absence of the risk SLG listed in Table 1.
The 4-LG1, having a no risk SLG, was the most frequent
in controls (45%) with similar presentation in males and
females, but it was significantly less frequent in JIA pa-
tients of both JIoA and JIpA subtypes (about 29% and 20%
respectively) and appears to be JIA protective with a strong
level of association (p < 0.001) with healthy phenotype in
common cohort and females. The 4-LG5 unites three con-
figurations, all having the rs2348071 risk genotype in com-
bination with risk genotype at the rs2295826 and/or
rs2295827 loci. The 4-LG5 was approximately three times
more frequent in JIA than in controls and two times more
frequent in females than in males of all JIA subtypes. This
genotype showed a strong association (p < 0.001) with JIA
in common and JIoA cohorts and the female phenotype.
Rarely observed in controls and JIA females (< 5%), the
rs2277460/rs2348071 double heterozygotes (4-LG6) were
rather frequent in JIA males (> 12%) and showed an asso-
ciation (p < 0.002) with JIpA in common cohort and with
JIoA in males.
The 4-LG2, 4-LG3, and 4-LG4 genotypes were observed
with similar frequencies in cases and controls and were
considered JIA neutral. The two remaining (4-LG7 and 4-
LG8) genotypes were rare in controls and only slightly more
frequent in JIA patients.
3.3. Four loci haplotype analysis
Table 3 provides information on the four-loci haplotype (4-
LH) spectrum and frequencies in the groups. Using the
assumption of random assortment of alleles, 24 haplotype
configurations were expected for four two-allele loci;
however, only 10 variants were identified in cases and con-
trols taken together, and all of them are implicated from the
4-LGs homozygous at all four loci and/or genotypes being
heterozygous only at one locus. The 4-LH1e4-LH6 haplo-
types were observed in both controls and case groups; the 4-
LH7e4-LH10 were identified only in JIoA females. The 4-LH1
(C-C-A-G) having the common alleles at all four loci was
found to be the most frequent in all groups and used as
reference haplotype in association analysis. The 4-LH4 (C-G-
T-A) having the risk alleles at the rs2295826 and rs2295827
and the rs2348071 minor allele A was found to be in strong
association (p< 0.001) with JIA including both JIoA and JIpA
subtypes in female and male cohorts. The 4-LH5 (A-C-A-G)
Table 3 Four-loci haplotypes (4-LHs) presentation and data on significant associations with juvenile idiopathic arthritis (JIA).
Group C
n Z 191
C-F
n Z 117
C-M
n Z 74
JIA
n Z 174
JIA-F
n Z 108
JIA-M
n Z 66
JIoA
n Z 107
JIoA-F
n Z 63
JIoA-M
n Z 44
JIpA
n Z 55
JIpA-F
n Z 39
JIpA-M
n Z 16
4-LG Number (%)
Full homozygote 89
(46.60)
54
(46.15)
35
(47.30)
49
(28.16)
25
(23.15)
24
(36.36)
34
(31.78)
17
(26.98)
17
(38.64)
12
(21.82)
7
(17.95)
5
(31.25)
Single locus heterozygote 65
(34.03)
36
(30.77)
29
(39.19)
66
(37.93)
44
(40.74)
22
(33.33)
34
(31.78)
23
(36.51)
11
(25.00)
24
(43.64)
17
(43.59)
7
(43.75)
Multiple loci heterozygote 37
(19.37)
27
(23.08)
10
(13.51)
59
(33.91)
39
(36.11)
20
(30.30)
39
(36.45)
23
(36.51)
16
(36.36)
19
(34.55)
15
(38.46)
4
(25.00)
Haplotype Loci Number (%)
1e2e3e4 382 234 148 348 216 132 214 126 88 110 78 32
4-LH-1Ref C-A-C-G 231
(60.47)
147
(62.82)
84
(56.76)
178
(51.15)
109
(50.46)
69
(52.27)
117
(54.67)
68
(53.97)
49
(55.68)
53
(48.18)
38
(48.72)
15
(46.88)
4-LH-2 C-A-C-A 86
(22.51)
45
(19.23)
41
(27.70)
72
(20.69)
45
(20.83)
27
(20.45)
32
(14.95)
19
(15.08)
13
(14.77)
27
(24.55)
19
(24.36)
8
(25.00)
4-LH-3 C-G-T-G 29
(7.59)
19
(8.12)
10
(6.76)
19
(5.46)
13
(6.02)
6
(4.55)
12
(5.61)
9
(7.14)
3
(3.41)
7
(6.36)
4
(5.13)
3
(9.38)
4-LH-4R C-G-T-A 11
(2.88)
11
(4.70)
d 37
(10.63)
25
(11.57)
12
(9.09)
25
(11.68)
14
(11.11)
11
(12.50)
11
(10.00)
10
(12.82)
1
(3.13)
Association in
the groups
P OR CI
JIA vs. C <0.001 4.365 2.192e8.693
JIoA vs. C <0.001 4.487 2.161e9.318
JIpA vs. C <0.05 4.358 1.826e10.401
4-LH-5 A-A-C-A 15
(3.93)
8
(3.42)
7
(4.73)
12
(3.45)
5
(2.31)
7
(5.30)
11
(5.14)
4
(3.17)
7
(7.95)
d d d
4-LH-6R A-A-C-G 10
(2.62)
4
(1.71)
6
(4.05)
22
(6.32)
11
(5.09)
11
(8.33)
9
(4.21)
4
(3.17)
5
(5.68)
12
(10.91)
7
(8.97)
5
(15.63)
Association in
the groups
P OR CI
JIA vs. C <0.05 2.855 1.338e6.093
JIpA vs. C <0.001 5.230 2.185e12.517
4-LH-7 A-G-T-G d d d 3 3 d 3 3 d d d d
4-LH-8 A-G-T-A d d d 2 2 d 2 2 d d d d
4-LH-9 C-G-C-G d d d 1 1 d 1 1 d d d d
4-LH-10 C-G-C-A d d d 2 2 d 2 2 d d d d
Superscripts “Ref” and “R” indicate the reference and risk haplotypes respectively. Single nucleotide polymorphism loci in the 1e2e3e4 haplotypes are given in the
rs2277460ers2295826ers2295827ers2348071 sequence. Risk alleles are indicated in bold and underlined. Probability of association < 0.002 is indicated in bold. Frequencies of the 4-LH7,
4-LH8, 4-LH9 and 4-LH10 haplotypes rare/absent in all groups (<3%) are not indicated in the table. In statistical analysis the 4-LH1 haplotype was considered as reference.
4-LG Z four-loci genotype; JIA Z juvenile idiopathic arthritis; JIoA Z juvenile idiopathic oligoarthritis; JIpA Z juvenile idiopathic polyarthritis; C Z control; F Z female; M Z male.
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Figure 1 Plasma proteasome level in juvenile idiopathic
oligoarthritis patients. Carriers of different four-locus geno-
types (4-LGs), 4-LG1, 4-LG2, 4-LG3, 4-LG4, and 4-LG5, were
represented by four, six, three, three, and seven patients
respectively. * p < 0.05, ** p < 0.001, # p > 0.05.
400 T. Sjakste et alhaving the only risk allele at the rs2277460 locus showed
strong (p < 0.001) association with JIpA.
3.4. Genotype dependent plasma proteasome
levels in JIoA patients
Plasma samples were available for 23 JIoA females, carriers
of five different 4-LGs (Figure 1). Females of 4-LG1
exhibited a plasma proteasome concentration of approxi-
mately 2000 ng/mL, which is similar to previously reported
plasma proteasome levels for healthy donors.25e27 Careers
of the 4-LG2 and 4-LG5 genotypes exhibited significantly
(p < 0.05 and p < 0.001) higher plasma proteasome levels.Figure 2 Consequences of the nucleotide substitutions on functi
arthritis associated single nucleotide polymorphisms of the PSMA6,
transcription factors. Upward and downward arrows indicate splic
SSA Z splicing site acceptor. Details are given in Supplementary THigh plasma proteasome levels were also detected in fe-
males of 4-LG3; however, the small number of patients in
this group did not allow the results to reach statistical
significance.
3.5. Eventual functional significance of the SNPs
allelic variants
Figure 2 summarizes results of the in silico analysis of the
functional significance of allele substitutions (only loci
detected as JIA susceptible were taken into account)
evaluated on the eventual sequence affinity to TFs and
splicing signals similarity, and on the homology to known
microRNAs and their precursors.
The major allele of only the rs2295826 locus potentially
assists in sequence affinity to TFs. These are proteins of the
CREB, MYT1 and PARF families. The rs2295826 minor allele
appears to abolish any sequence affinity to TFs. Minor al-
leles at the rs2277460, rs2295827, and rs2348071 loci
potentially assist in the binding of proteins belonging to the
BARBIE box, CART, BRN5, LHXF, HOXF, HBOX, and MEF2
families.
Major alleles of both the rs2295826 and rs2295827 loci
potentially assist in the generation of additional branch
points; the rs2295826 major allele creates a splice site
acceptor and targets for the hnRNP A1; the hnRNP A1 target
motif is also generated in presence of both the rs2277460
and rs2348071 minor alleles. Major alleles of the rs2295826
and rs2348071 and minor alleles of all loci besides the
rs2295826 could potentially change the sequence similarity
to a number of splicing enhancers and/or silencers (Figure 2
and Suppl Table 3).
The rs2295827 major and rs2295826 minor allele in-
crease sequence similarity to hsa-miR-603 and hsa-miR-
5584-3p, respectively (Figure 2).onal potential of the genome site harboring juvenile idiopathic
PSMC6, and PSMA3 genes. Only family names are indicated for
ing enhancers and silencers, respectively. BP Z branch point;
able 3.
PSMA6/PSMC6/PSMA3 & juvenile idiopathic arthritis 4014. Discussion
The aim of the current study was to evaluate six SNPs
belonging to the PSMA6 (rs2277460 and rs1048990), PSMA3
(rs2348071), PSMB5 (rs11543947), and PSMC6 (rs2295826
and rs2295827) proteasomal genes for association with JIA
with adjustment by JIA subtype and sex.
From all SNPs analyzed, the rs1048990 (PSMA6 c.-8C>G)
located in the 50- untranslated region of the gene is the
most studied SNP of proteasomal genes, which has been
widely genotyped for association with cardiovascular
diseases,Suppl 1e12,14,15 T2DM,Suppl 3,14 and children obesi-
ty.Suppl 16 Summarizing the results obtained by different
teams, we suggested a potential of the rs1048990 to influ-
ence JIA susceptibility. However, we did not find any as-
sociation between the rs1048990 polymorphism and JIA in
Latvians. Similarly, locus did not show any association with
obesity in Latvian children.Suppl 16 In turn, the rs2277460 of
the promoter region of the same gene (PSMA6 c.-110C>A)
has been detected as JIA susceptible locus. This conclusion
is based on the results of the subtype- and sex-specific
disease association with rare allele A, heterozygous SLG,
4-LG6 heterozygous at the rs2277460, and 4-LH6 haplotype
both having the rs2277460 rare allele in its structure (Tables
1e3).
It had been reported that the rs2230087 polymorphism
of the PSMB5 gene (30-untranslated region) is associated
with T2DM.Suppl 9 In our study we were interested in the
rs11543947 of the same gene locating in exon 1 or intron 1
(PSMB5 c.70C>T or PSMB5 c.-112þ300C>T, respectively)
depending of transcript variant. This SNP did not show any
association with JIA in our study.
The rs2295826 and rs2295827 loci locate in close vicinity
to each other in intron 1 of the PSMC6 gene (PSMC6 c.86-
104A>G and PSMC6 c.86-46C>T respectively). Linkage be-
tween loci is not complete, and rare GC haplotypes were
observed in our study similar to data obtained for Tuscans in
Italy. Rare alleles of these loci and their risk SLGs showed
(dominant model) JIoA subtype-specific association by
themselves and as component of risk 4-LG5 genotype and
risk 4-LH4 haplotype.
The rs2348071 locus belongs to intron 7 of the PSMA3
gene (PSMA3 c.543þ138G>A or c.522þ138G>A depending
of transcript variant). Heterozygous genotype GA was found
to be associated mostly with JIpA. In 4-LG structures, the
rs2348071 heterozygotes were involved in both risk 4-LG5
and 4-LG6. Interestingly, the rs2348071 heterozygotes were
implicated previously as an obesity risk factor in Latvian
children with a family history of obesity.Suppl 16
It is important to note that strength of association with
the disease was much stronger for combination of several
risk SLGs than for any individual risk SLG. Therefore, we
have reported here for the first time evidence of an asso-
ciation between JIA and genetic variants in the PSMA6/
PSMC6/PSMA3 gene cluster represented by combinations of
at least two risk SLGs in a particular 4-LG, namely 4-LG5
(risk rs2295826/rs2295827/rs2348071) and 4-LG6 (risk
rs2277460/rs2348071). The 4-LG1 having no risk SLGs in its
composition showed strong association with healthy
phenotype (p < 0.001).
The JIA-associated SNPs discovered in our study poten-
tially could be themselves primarily susceptible to disease orlinked with other primary genetic variations linked to dis-
ease. It appears that both scenarios are possible. Concerning
chromosome 14, several loci potentially susceptible to
autoimmunediseases have been reported in different human
populations.17e24 The functional significance of the discov-
ered allele substitutions is to be clarified. We attempted to
shed more light on the problem using two approaches.
First, we evaluated plasma proteasome level in JIoA fe-
males of different 4-LGs and found significantly increased
levels of plasma proteasomes in JIoA female carriers of the 4-
LG5 risk genotype in comparison to carriers of protective 4-
LG1 (p < 0.001) genotype. Earlier, circulating proteasomes
were suggested as markers in autoimmune diseases.8 Con-
centration of circulating proteasomes was shown to be sub-
stantially elevated in patients with rheumatoid8 and
psoriatic9 arthritis. The 20S proteasome has been identified
as a target of the humoral autoreactive immune response in
patients with systemic inflammatory diseases including
autoimmune myositis,10 primary Sjo¨gren’s syndrome,11
dilated cardiomyopathy,12 systemic lupus erythemato-
sus,10,13,14 multiple sclerosis,15 and psoriatic arthritis.14 The
proteasomal inhibitor MG132 has been reported to reduce
the severity of arthritis and reverse the pain behavior in the
arthritic rat models.16 To our knowledge, plasma levels of
factors within the UPS have not been yet evaluated in JIA,
and here we report data on that for the first time.
Second, we have evaluated eventual functional signifi-
cance of allele substitutions on sequence affinity to TFs,
splicing signals similarity and on the homology to known
microRNAs and their precursors.
The major allele of the rs2295826 potentially assists to
sequence affinity for TFs of CREB, MYT1, and PARF families
known to be involved in regulation of multiple physiological
processes and control of the circadian clock.28e30 CREB-
related TFs are especially interesting with respect of JIA
pathogenesis, as they are known to be essential for osteo-
blast differentiation and function,28 and they have been
implicated in immune response.29 It is of interest that
expression of CREB, MYT1, and PARF proteins potentially
could share the same epigenetic mechanism of regulation
by hsa-miR-1264 originated from the X chromosome and
potentially be differently expressed and differently
involved in epigenetic network in females and males (data
not shown).
The presence of a minor allele at the rs2277460 locus
creates a binding site to the BARBIE box proteins reported to
be involved in signal transduction pathways during devel-
opment31 and modulation of innate immunity.32 Sequences
having minor alleles at the rs2295827 and rs2348071 sites
can potentially bind CART proteins responsible for bone and
cartilage development.33 Moreover, the rs2295827 and
rs2348071 minor alleles could assist in sequence affinity to
BRN5, LHXF, MEF2, and HBOX factors known to mediate
transcriptional control of neuronal differentiation34e37 and
HOXF family NANOG.01 factor generally involved in signal
transduction pathways during development.38
Similar to TFBSs, patterns of predicted splicing signals
are allele specific. The rs2295826 and rs2348071 loci create
a number of allele-specific targets for splicing enhancers
and silencers. Only minor allele of the rs2277460 and only
major allele of the rs2295827 is functional in this respect.
Nucleotide substitutions at the rs2277460, rs2295826, and
402 T. Sjakste et alrs2348071 define affinity of corresponding sequences to the
hnRNP A1 known as alternative splicing repressor39 and
factor facilitating processing of specific microRNAs.40 The
above mentioned allele-specific differences in spectra of
splicing signals could potentially significantly affect genes
splicing activity and affect UPS efficiency.
Therefore, all of the above types of associations
revealed and data on functional significance of allele sub-
stitutions are in good agreement between themselves and
provide evidence that: (1) variations at the rs2277460,
rs2295826, rs2295827, and rs2348071 loci could assist JIA
susceptibility; (2) combination of the rs2348071 and
rs2295826 and/or rs2295827 risk genotypes (4-LG5) repre-
sents the genetic module highly associated with both JIoA
and JIpA and JIA female phenotype and plasma proteasome
level in JIoA females; (3) combination of the rs2348071 and
rs2277460 risk genotypes (4-LG6) represents the genetic
module presumably associated with JIpA and male pheno-
type; (4) nucleotide substitutions affect the potential of
encompassing sequences to create splicing signals, TFBSs
and microRNAs; and (5) the PSMA6/PSMC6/PSMA3 genetic
variants and multiloci genetic modules could be suggested
as JIA subtype- and sex-specific risk factors.
In conclusion it should be mentioned that, despite the
rather small number (174/191 of cases/controls), this study
can be considered as representative for the small Latvian
population (< 2 million). Keeping in mind that JIA unites
several clinically different subtypes, and that this disease
tends to affect females more than males, we have applied
stratification by JIA-subtype and sex. Due to the small
subgroups, we sometimes could not reach significance.
However, when significance was achieved, we obtained
interesting results to be investigated with reference to
other populations.
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